Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity

The safety and feasibility of dendritic cell (DC)-based immunotherapies in cancer management have been well documented after more than twenty-five years of experimentation, and, by now, undeniably accepted. On the other hand, it is equally evident that DC-based vaccination as monotherapy did not ach...

Descripción completa

Detalles Bibliográficos
Autores principales: Lamberti, María Julia, Nigro, Annunziata, Mentucci, Fátima María, Rumie Vittar, Natalia Belén, Casolaro, Vincenzo, Dal Col, Jessica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151083/
https://www.ncbi.nlm.nih.gov/pubmed/32178288
http://dx.doi.org/10.3390/pharmaceutics12030256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151083/
https://www.ncbi.nlm.nih.gov/pubmed/32178288
http://dx.doi.org/10.3390/pharmaceutics12030256

Ejemplares similares